[1]Yagi S, Yoshikawa E, Futatsubashi M, et al. Progression from unilateral to bilateral parkinsonism in early Parkinson disease: implication of mesocortical dopamine dysfunction by PET[J]. J Nucl Med, 2010, 51(8): 1250-1257.
[2]Kono S, Shirakawa K, Ouchi Y, et al. Dopaminergic neuronal dysfunction associated with parkinsonism in both a Gaucher disease patient and a carrier[J]. J Neurol Sci, 2007, 252(2): 181-184.
[3]Park E, Hwang Y M, Lee C N, et al. Differential diagnosis of patients with inconclusive Parkinsonian features using [18F]FP-CIT PET/CT[J]. Nucl Med Mol Imaging, 2014, 48(2): 106-113.
[4]Fukae J, Fukaya C, Oshima H, et al. Successful treatment with bilateral deep brain stimulation of the subthalamic nucleus for benign tremulous parkinsonism[J]. Rinsho Shinkeigaku, 2014, 54(6): 511-414.
[5]Konishi T, Kono S, Fujimoto M, et al. Benign hereditary chorea: dopaminergic brain imaging in patients with a novel intronic NKX2.1 gene mutation[J]. J Neurol, 2013, 260(1): 207-213.
[6]Rinne J O, Laihinen A, Nagren K, et al. PET examination of the monoamine transporter with [11C]beta-CIT and [11C]beta-CFT in early Parkinson's disease[J]. Synapse, 1995, 21(2): 97-103.
[7]Ouchi Y, Kanno T, Okada H, et al. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study[J]. Ann Neurol,1999, 46(5): 723-731.
[8]Yoder K K, Hutchins G D, Mock B H, et al. Dopamine transporter binding in rat striatum: a comparison of [O-methyl-11C]beta-CFT and [N-methyl-11C]beta-CFT[J]. Nucl Med Biol, 2009, 36(1): 11-16.
[9]Kawamura K, Oda K, Ishiwata K. Age-related changes of the [11C]CFT binding to the striatal dopamine transporters in the Fischer 344 rats: a PET-study[J]. Ann Nucl Med, 2003,17(3): 249-253.
[10]Liu L, Zhang W, Gong X, et al. Relation between microPET imaging and rotational behavior in a parkinsonian rat model induced by medial forebrain bundle axotomy[J]. Behav Brain Res, 2014, 265: 148-154.
[11]Saiki H, Hayashi T, Takahashi R, et al. Objective and quantitative evaluation of motor function in a monkey model of Parkinson's disease[J]. J Neurosci Methods, 2010,190(2): 198-204.
[12]Zhang Y F, Wang X Y, Cao L, et al. Effects of hypoxic-ischemic brain injury on striatal dopamine transporter in newborn piglets: evaluation of 11C-CFT PET/CT for DAT quantification[J]. Nucl Med Biol, 2011, 38(8): 1205-1212.
[13]Ishibashi K, Oda K, Ishiwata K, et al. Comparison of dopamine transporter decline in a patient with Parkinson's disease and normal aging effect[J]. J Neurol Sci, 2014, 339(1-2): 207-209.
[14]文富华,邓怀福,王红亮,等. 多巴胺转动蛋白显像剂11C-β-CFT的全自动化合成[J]. 同位素,2014,24(4):193-197.Wen Fuhua, Deng Huaifu, Wang Hongliang, et al. Full automated synthesis of 11C-β-CFT as a dopamine transporter imaging agent[J]. Journal of Isotopes, 2014, 24(4):193-197(in Chinese).
[15]张锦明,田嘉禾,郭喆,等. 在线自动化制备多巴胺转运蛋白显像剂11C-β-CFT[J]. 中华核医学杂志,2005,25(3):142-145.Zhang Jinming, Tian Jiahe, Guo zhe, et al. Automated on-line preparation of 11C-β-CFT, a dopamine transporter imaging agent[J]. Chin J Nucl Med, 2005, 25(3): 142-145(in Chinese).
[16]李海峰,陈志军,张晓军,等. 11C-标记雷氯必利合成效率的影响因素[J]. 同位素,2016,29(1):12-18.Li Haifeng, Chen Zhijun, Zhang xiaojun, et al. Optimization of the synthetic efficiency of the 11C-Raclopride[J]. Journal of Isotopes, 2016, 29(1): 12-18(in Chinese). |